Hansa Biopharma sees Q4 revenue jump 135% to SEK 76 million while advancing US regulatory plans. The company submitted a BLA to the FDA for imlifidase and raised SEK 671.5 million in a directed share issue to support commercialization. #HansaBiopharma #LifeScience
0
0
0
0